Covered recipient · General Payments record
GANAPATHI RAO MOKA
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2023
$4,319.42
- Reported across 151 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $485.27 | 18 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $209.65 | 13 |
| Edwards Lifesciences Corporation | $122.89 | 1 |
| ABBVIE INC. | $115.81 | 2 |
| Relypsa, Inc. | $36.92 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.73 | 07/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997936365 | CMS |
| ABBVIE INC. | $92.08 | 07/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997936367 | CMS |
| Edwards Lifesciences Corporation | $122.89 | 06/30/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1023201727 | CMS |
| Novo Nordisk Inc | $20.71 | 02/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696571 | CMS |
| Novo Nordisk Inc | $4.70 | 03/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696471 | CMS |
| Novo Nordisk Inc | $22.72 | 03/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696591 | CMS |
| Novo Nordisk Inc | $19.18 | 03/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696551 | CMS |
| Novo Nordisk Inc | $22.55 | 03/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696581 | CMS |
| Novo Nordisk Inc | $20.52 | 05/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696561 | CMS |
| Novo Nordisk Inc | $14.69 | 06/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696511 | CMS |
| Novo Nordisk Inc | $5.99 | 06/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696481 | CMS |
| Novo Nordisk Inc | $17.04 | 06/26/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696531 | CMS |
| Novo Nordisk Inc | $15.84 | 07/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696521 | CMS |
| Novo Nordisk Inc | $17.44 | 08/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696541 | CMS |
| Novo Nordisk Inc | $14.54 | 08/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696501 | CMS |
| Novo Nordisk Inc | $13.73 | 12/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000696491 | CMS |
| Vifor Pharma, Inc. | $22.47 | 03/24/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1013115559 | CMS |
| Vifor Pharma, Inc. | $14.45 | 05/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1013127181 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.